Engineering ABO histocompatibility in transplant and beyond

identifying appropriate public and private funding sources.CAR T-cell therapy for AML continues to face unique, complex challenges including target selection, design, toxicity prevention/management in a vulnerable patient population, and coordination with alloHCT.VBP301, although terminated early, illustrates the feasibility of manufacturing and delivering donorderived CAR T cells for patients with AML with relapse (or high risk of relapse) after -alloHCT and opportunities to optimize this promi